Britannia Life Sciences Inc.
BLAB
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -97.80K | -875.80K | -539.40K | -4.38M | 393.50K |
| Total Depreciation and Amortization | 39.50K | 38.80K | 37.30K | 55.70K | 50.00K |
| Total Amortization of Deferred Charges | 33.90K | 26.40K | 17.60K | 36.30K | -- |
| Total Other Non-Cash Items | 117.70K | 705.80K | 525.40K | 4.69M | -722.50K |
| Change in Net Operating Assets | 401.30K | 170.80K | -31.30K | -158.90K | 702.40K |
| Cash from Operations | 494.60K | 66.00K | 9.50K | 236.70K | 423.40K |
| Capital Expenditure | -9.00K | -1.90K | -1.70K | -8.00K | -4.70K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | 1.80K | -687.00K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.70K | -66.80K | -61.30K | -125.10K | -8.50K |
| Cash from Investing | -73.70K | -68.70K | -63.00K | -131.30K | -700.20K |
| Total Debt Issued | 0.00 | 771.50K | -- | 27.00K | -- |
| Total Debt Repaid | -574.50K | -578.40K | -520.00K | -588.40K | -481.50K |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -410.40K | 141.60K | -380.00K | -416.40K | -353.90K |
| Foreign Exchange rate Adjustments | -1.10K | 33.30K | 9.40K | 19.20K | 39.70K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.40K | 172.20K | -424.00K | -291.90K | -591.00K |